Leading American solid-state battery innovator, backed by global automakers and rapidly expanding into defense & aerospace, robotics, and hyperscale data centers, enters public markets with $1.3 billion equity value BOSTON, June 08, 2026 (GLOBE NEWSWIRE) — Factorial Inc. (“Factorial”), a U.S. developer of solid-state battery technology, announced today that it has completed its previously announced business combination with Cartesian Growth Corporation III, a publicly traded special purpose acquisition company. The combined company will operate as Factorial Energy Inc., and its Series A common stock and warrants are expected to begin trading on the Nasdaq Stock Market (“Nasdaq”) under the ticker symbols “FAC” and “FACWW”, respectively, on June 8, 2026. The transaction implies an equity value of approximately $1.3 billion and...

8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: Rathbones Group Plc(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.  (c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree A consortium comprising LondonMetric Property plc and Schroder Real Estate Investment Trust Limited(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  (e)   Date...

Combined company to operate as Treeline Biosciences, advancing a deep pipeline of small molecule inhibitors, protein degraders and targeted therapy antibody-drug conjugates Company to be led by Treeline CEO and co-founder Josh Bilenker, MD, and experienced team of proven drug developers Treeline’s pipeline includes three Phase 1 programs with multiple anticipated clinical data readouts beginning in 2027 Well capitalized with over $900 million in cash expected at closing, providing runway into 2029 Supplemental investor materials, including management remarks, posted on Standard BioTools website BOSTON, Mass. and WATERTOWN, Mass., June 08, 2026 (GLOBE NEWSWIRE) — Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools”) and Treeline Biosciences, Inc. (“Treeline”) today announced they have entered into a definitive merger agreement...

DEMIRE: Major shareholders launch structured sale processMajor shareholders AEPF III 15 Sarl (“AEPF”), a fund vehicle managed by Apollo Global Management, and Wecken & Cie. are launching a structured process to sell their approximately 90% stake No plans to sell via the stock exchange Objective: A new anchor investor with financial strength and a strategic contribution Foundation laid through stabilisation, portfolio adjustments and financial measuresLangen, 8 June 2026. DEMIRE Deutsche Mittelstand Real Estate AG (ISIN: DE000A0XFSF0) (“DEMIRE” or the “Company) announces that its major shareholders AEPF III 15 Sarl (“AEPF”), a fund vehicle managed by Apollo Global Management, and Wecken & Cie., in alignment with the Company, have initiated a structured process to explore the sale of their combined stake of around 90% in DEMIRE....

Kneat Shareholders to Receive C$6.50 Per Share in Cash, a 40% Premium to Kneat’s Unaffected Share Price Transaction to accelerate Kneat’s leadership in digital validation and quality process automation for life sciences LIMERICK, Ireland, June 08, 2026 (GLOBE NEWSWIRE) — kneat.com, inc. (TSX: KSI) (OTCQX: KSIOF), (“Kneat” or the “Company”), the global leader in digital validation and quality process automation, is pleased to announce that it has entered into a definitive arrangement agreement (the “Arrangement Agreement”) with an affiliate of Thoma Bravo, L.P. (“Thoma Bravo” or the “Purchaser”), the world’s largest software-focused investment firm, whereby the Purchaser will acquire all of the issued and outstanding common shares (the “Shares”) of the Company, subject to obtaining shareholder and other customary approvals...

Combined company to accelerate Suniva’s U.S. solar cell manufacturing expansion and market leadership, backed by SUNation’s established market presence, deep end-market relationships, and Nasdaq-listed platform  Suniva to merge with SUNation, combined company expected to operate under the Suniva name and continue SUNation’s Nasdaq listing Transaction expected to enhance domestic solar capacity, support margin expansion and broaden access to U.S. capital markets to fund future growth and strategic opportunities RONKONKOMA, N.Y. and NORCROSS, Ga., June 08, 2026 (GLOBE NEWSWIRE) — SUNation Energy, Inc. (Nasdaq: SUNE) (“SUNation”), a leading provider of residential and commercial solar energy systems, battery storage solutions, and comprehensive energy services, and Suniva, (“Suniva”) the largest and oldest U.S. merchant manufacturer...

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree ADVANCED MEDICAL SOLUTIONS GROUP PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date...

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree ANIMALCARE GROUP PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position...

Creates a scaled global provider of specialty ingredient solutions for a healthier, tastier and more sustainable future of food  Broadens Ingredion’s specialty ingredients platform across texturants, sugar reduction, and fortification, adding complementary capabilities in multi-ingredient systems and recipe development Expands Ingredion’s ability to address customer needs across a wider range of end use categories and applications Brings together complementary geographic supply networks across the Americas, Europe, the Middle East and Africa, and Asia Pacific to deliver faster, more reliable and cost-effective ingredients and solutions for customers and consumers worldwideWESTCHESTER, Ill., June 08, 2026 (GLOBE NEWSWIRE) — Ingredion Incorporated (NYSE: INGR) (“Ingredion”), a leading global provider of ingredient solutions to...

Transaction Establishes a Large-Scale Pharmaceutical Platform in Japan and Strengthens Commercial Capabilities Across Key Therapeutic Areas TOKYO, June 07, 2026 (GLOBE NEWSWIRE) — GNI Group Co., Ltd. (TSE: 2160) today announced that it has entered into an agreement to acquire 100% of the shares of Ayumi Pharmaceutical Holdings Co., Ltd. from shareholders led by Blackstone. The transaction values Ayumi Pharmaceutical Holdings at approximately ¥44.8 billion and will make the company a wholly owned subsidiary of GNI Group. The acquisition significantly expands GNI Group’s commercial presence in Japan and establishes a large-scale pharmaceutical platform that is expected to accelerate the introduction of innovative therapies, biosimilars, and internally developed products into the Japanese market. Following the transaction, GNI Group...